Results 231 to 240 of about 35,888 (296)

Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS + randomized controlled trial study protocol. [PDF]

Addict Sci Clin Pract
Miller SE, Dukes KA, Damato-MacPherson C, Psaros C, Scott NA, Taylor JL, Muroff J, Winter MR, Skiba LE, Lugo H, Cruz R, Ruiz-Mercado G, Crawford ND, Mayer KH, Assoumou SA.   +14 more
europepmc   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

Training in medications for opioid use disorder and buprenorphine prescribing in the post X-waiver era: Insights from a nationwide, multispecialty survey. [PDF]

Prev Med
Kim-Vences SIH, Nguyen J, Hirth JM, Suen KP, Keough CA, Zoorob R, Kowalchuk AA.   +6 more
europepmc   +1 more source

Aligning Efforts to Boost Medications for Opioid Use Disorder and Pre-Exposure Prophylaxis for HIV. [PDF]

J Gen Intern Med
Tilhou AS, Assoumou SA, Samet JH.
europepmc   +1 more source

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Medicaid Patients With ED Visits For Overdose: Disparities In Initiation Of Medications For Opioid Use Disorder. [PDF]

Health Aff (Millwood)
Nguyen T, Jiao Y, Lee SS, Lagisetty P, Bohnert A, Kocher KE, Chua KP.   +6 more
europepmc   +1 more source

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial

Addiction, EarlyView.
Abstract Background and aims Individuals with opioid use disorder (OUD) frequently present with co‐occurring mental health conditions such as depression and posttraumatic stress disorder (PTSD), along with other mental health substance use disorders, physical health conditions and social determinants that together comprise ‘clinical complexity ...
Megan S. Schuler, Rebecca Weir, Colleen M. McCullough, Grace M. Hindmarch, Beth Ann Griffin, Kirsten Becker, Lisa S. Meredith, Katherine E. Watkins   +7 more
wiley   +1 more source

Editorial: Reviews in opioid use disorders

Frontiers in Public Health
Wendy Walwyn, Kirk E. Evoy, Kirk E. Evoy
doaj   +1 more source

Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial

Addiction, EarlyView.
Abstract Background and aims Individuals who engage in illicit or nonmedical opioid use may have elevated risk of health and social consequences, including progression to opioid use disorder (OUD). Preventive interventions to reduce this risk are lacking. This trial tested the impact of a primary care‐integrated collaborative care approach for reducing
Jennifer McNeely, Geetha A. Subramaniam, Rebecca Stone, Shayna Mazel, Noa Appleton, Yasna Rostam‐Abadi, Amanda M. Bunting, Yidan Shi, Travis I. Lovejoy, Lillian Gelberg, Donna Beers, Margaret Kline, Song Zhang, Tobie Kim, Ashley Case, Jennifer McCormack, Michael A. Incze, Jane M. Liebschutz, the STOP trial site principal investigators, Karen Alexander, Seuli Bose Brill, Sarah Kawasaki, Adam J. Gordon, Hyunouk Hong   +23 more
wiley   +1 more source

Concerns About Medications for Opioid Use Disorder Among American Indian Community Members: A Qualitative Secondary Analysis. [PDF]

Public Opin Q
Grubin F, Neavill ME, Sawyer T, Larson A, Maltaverne E, Skewes MC.   +5 more
europepmc   +1 more source